切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2024, Vol. 17 ›› Issue (06) : 855 -860. doi: 10.3877/cma.j.issn.1674-6902.2024.06.002

论著

以全球视角对中国慢性阻塞性肺疾病负担及未来趋势分析
罗宸婧1, 盛芳芳1, 张静1, 王关嵩2, 秦蘅2,(), 顾鹏1,()   
  1. 1.400037 重庆,陆军(第三)军医大学第二附属医院药学部
    2.400037 重庆,陆军(第三)军医大学第二附属医院呼吸与危重症医学科
  • 收稿日期:2024-08-07 出版日期:2024-12-25
  • 通信作者: 秦蘅, 顾鹏
  • 基金资助:
    重庆市科卫联合医学攻关重大项目(2024GGXM001)

Global perspective on the burden of chronic obstructive pulmonary disease in China and future trends analysis

Chenjing Luo1, Fangfang Sheng1, Jing Zhang1, Guansong Wang2, Heng Qin2,(), Peng Gu1,()   

  1. 1.Department of Pharmacy, Xinqiao Hospital, Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
    2.Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
  • Received:2024-08-07 Published:2024-12-25
  • Corresponding author: Heng Qin, Peng Gu
引用本文:

罗宸婧, 盛芳芳, 张静, 王关嵩, 秦蘅, 顾鹏. 以全球视角对中国慢性阻塞性肺疾病负担及未来趋势分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(06): 855-860.

Chenjing Luo, Fangfang Sheng, Jing Zhang, Guansong Wang, Heng Qin, Peng Gu. Global perspective on the burden of chronic obstructive pulmonary disease in China and future trends analysis[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(06): 855-860.

目的

分析1990-2021 年中国慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的疾病负担及2022-2050 年的变化趋势,以期为COPD 防治提供参考依据。

方法

提取全球疾病负担研究2021 数据库中1990-2021 年中国COPD 疾病负担、危险因素等相关数据,应用百分比变化及年估计变化百分比分析疾病负担演变情况,并对不同性别、年龄人群进行分层分析。 对所有风险因素所导致的死亡进行归因分析,使用贝叶斯年龄-时期-队列模型预测2022-2050 年COPD 疾病负担变化趋势。

结果

2021 年我国COPD 发病4 434 437.77 例,死亡1 285 433.17 例,伤残调整寿命年为23 640 320.96例年,分别较1990 年增加105.20%,3.84%和-9.42%。 1990-2021 年COPD 的年龄标准化发病率、年龄标准化病死率和年龄标准化伤残调整寿命年率呈现下降趋势,年估计变化百分比分别为-0.84%,-4.25%和-4.19%。 2021 年男性发病2 226 848.07 例,死亡752 026.94 例,伤残调整寿命年13 480 743.00例年,分别较1990 年增加112.81%、17.28%和-2.98%;女性发病2 207 589.70 例,死亡533 406.24例,伤残调整寿命年10 159 577.96 人年,分别较1990 年增加98.06%、-10.61%和-16.75%,显示出性别差异。 疾病负担随着年龄增长显著增加,男性发病和伤残调整寿命年高峰分别为65~69 岁和70~74 岁,女性为70~74 岁和80~84 岁;死亡高峰在80~84 岁,无性别差异。 导致COPD 死亡的危险因素随时间发生变化,近5 年吸烟为首位危险因素,男、女性最常见危险因素分别为吸烟和颗粒物污染。预计2022-2050 年COPD 的年龄标准化发病率、年龄标准化病死率、年龄标准化伤残调整寿命年率将持续下降,2050 年分别将下降至139.71/10 万、15.80/10 万和362.03/10 万。

结论

我国COPD 疾病负担仍较为严峻,应针对高危人群及风险因素制定有效防治策略。

Objective

To analyze the disease burden of chronic obstructive pulmonary disease(COPD) in China from 1990 to 2021,and the trend of change from 2022 to 2050,in order to provide a reference for the prevention and control of COPD.

Methods

Chinese disease burden and risk factors of COPD from 1990 to 2021 were extracted in the Global Burden of Disease 2021.Percentage change and estimated annual percentage change were applied to analyze the evolution of the disease burden.And which in different sex and age groups was also analyzed.Deaths due to all risk factors were attributed and Bayesian age-periodcohort modeling was used to predict trends of COPD from 2022 to 2050.

Results

The number of incident,death,disability-adjusted life years(DALYs) in 2021 were 4 434 437.77,1 285 433.17 and 23 640 320.96,which was 105.20%,3.84%,and -9.42% higher than 1990,reapectively.The age-standardized rate of incident,death and DALYs showed a downward trend from 1990 to 2021,estimated annual percentage change was -0.84%,-4.25% and -4.19%,reapectively.In 2021,the number of incident,death,disability-adjusted life years(DALYs) were 2 226 848.07,752 026.94 and 13 480 743.00 among males,which was 112.81%,17.28% and -2.98% higher than 1990,reapectively.For females,there were 2 207 589.70 cases of incidence and 533 406.24 deaths,with 10 159 577.96 DALYs,representing 98.06%,-10.61% and -16.75% higher than 1990,reapectively.Indicating a gender difference.Disease burden increased significantly with age,with the peak of incidence and DALYs for males were in the 65-69 and 70-74 years old,and for females in the 70-74 and 80-84 years old.The peak in deaths for both genders was in the 80-84 age group,with no gender difference.The risk factors leading to COPD-related deaths have changed over time,with smoking being the leading risk factor in recent five years,and the most common risk factors for males and females being smoking and particulate matter pollution,respectively.The age-standardized rate of incidence,death and DALYs will continued decrease from 2022 to 2050.,with expected decreases to 139.71/100 000、15.80/100 000 and 362.03/100 000 by 2050,respectively.

Conclusion

The disease burden of COPD in China remains severe,and effective prevention and treatment strategies should beformulated for high-risk populations and risk factors.

表1 1990 和2021 年中国COPD 疾病负担变化
图1 1990-2021 年不同性别COPD 疾病负担变化趋势。 注:A:年龄标准化发病率;B:年龄标准化病死率;C:年龄标准化伤残调整寿命年率。 incidence=发病;death=死亡;DALYs=伤残调整寿命年
图2 2021 年40 岁及以上各年龄段COPD 疾病负担。 注:A:发病例数及率;B:死亡例数及率;C:伤残寿命调整年及率。incidence=发病;death=死亡;DALYs=伤残调整寿命年
图3 1990 和2021 年COPD 归因于三级危险因素的疾病负担情况。 注:A:1990 年;B:2021 年;proportion of deathsattributable to risk=可归因风险的死亡比例;ambient ozone pollution= 环境臭氧污染; high temperature = 高温; low temperature=低温;occupational particulate matter,gases,and fumes=职业性颗粒物/气体/烟雾;particulate matter pollution=颗粒物污染;second hand smoke=二手烟;smoking=吸烟
图4 2022-2050 年COPD 疾病负担预测结果。 注:A.年龄标准化发病率;B.年龄标准化病死率;C.年龄标准化伤残调整寿命年率。 agestd-rate=年龄标准化率
1
Celli B,Fabbri L,Criner G,et al.Definition and nomenclature of chronic obstructive pulmonary disease:Time for its revision[J].Am J Respir Crit Care Med,2022,206(11):1317-1325.
2
Guerreiro I,Soccal PM.COPD and phenotypes[J].Rev Med Suisse,2019,15(671):2082-2086.
3
Bagdonas E,Raudoniute J,Bruzauskaite I,et al.Novel aspects of pathogenesis and regeneration mechanisms in COPD[J].Int J Chron Obstruct Pulmon Dis,2015,10:995-1013.
4
GBD Chronic Respiratory Disease Collaborators.Prevalence and attributable health burden of chronic respiratory diseases,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet Respir Med,2020,8(6):585-596.
5
GBD 2015 Chronic Respiratory Disease Collaborators.Global,regional,and national deaths,prevalence,disability-adjusted life years,and years lived with disability for chronic obstructive pulmonary disease and asthma,1990-2015:A systematic analysis for the Global Burden of Disease Study 2015[J].Lancet Respir Med,2017,5(9):691-706.
6
Yin P,Wu J,Wang L,et al.The burden of COPD in China and its provinces:Findings from the Global Burden of Disease Study 2019[J].Front Public Health,2022,10:859499.
7
Lozano R,Naghavi M,Foreman K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet,2016,380(9859):2095-2128.
8
Hu W,Fang L,Zhang H,et al.Global disease burden of COPD from 1990 to 2019 and prediction of future disease burden trend in China[J].Public Health,2022,208:89-97.
9
Smith MC,Wrobel JP.Epidemiology and clinical impact of major comorbidities in patients with COPD[J].Int J Chron Obstruct Pulmon Dis,2014,9:871-888.
10
Mathers CD,Loncar D.Projections of global mortality and burden of disease from 2002 to 2030[J].PLoS Med,2006,3(11):e442.
11
GBD 2021 Diseases and Injuries Collaborators.Global incidence,prevalence,years lived with disability (YLDs),disability-adjusted life-years (DALYs),and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations,1990-2021:A systematic analysis for the Global Burden of Disease Study 2021[J].Lancet,2024,403(10440):2133-2161.
12
赵军一,赵 凤,曲冰佳,等.1990-2019 年中国类风湿性关节炎疾病负担现状和趋势分析[J].中国卫生统计,2024,41(3):344-348,353.
13
Organization WH.ICD-10:International statistical classification of diseases and related health problems :tenth revision[J].Acta Chir Iugosl,2010,56(3):65-69.
14
张荣强,李凤英.年估计百分比变化与平均增长速度在公共卫生领域中的应用比较[J].中国卫生统计,2015,32(2):328-329,332.
15
Zhang L,Tong Z,Han R,et al.Spatiotemporal trends in global burden of rheumatic heart disease and associated risk factors from 1990 to 2019[J].Int J Cardiol,2023,384:100-106.
16
Zhang T,Sun L,Yin X,et al.Burden of drug use disorders in the United States from 1990 to 2021 and its projection until 2035:results from the GBD study[J].BMC Public Health,2024,24(1):1639.
17
Halpin DMG,Celli BR,Criner GJ,et al.The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries[J].Int J Tuberc Lung Dis,2019,23(11):1131-1141.
18
Meghji J,Mortimer K,Agusti A,et al.Improving lung health in low-income and middle-income countries:from challenges to solutions[J].Lancet,2021,397(10277):928-940.
19
GBD 2013 Mortality and Causes of Death Collaborators.Global,regional,and national age-sex specific all-cause and cause-specific mortality for 240 causes of death,1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J].Lancet,2015,385(9963):117-171.
20
Christenson SA,Smith BM,Bafadhel M,et al.Chronic obstructive pulmonary disease[J].Lancet,2022,399(10342):2227-2242.
21
Mannino DM,Buist AS.Global burden of COPD:risk factors,prevalence,and future trends[J].Lancet,2007,370(9589):765-773.
22
Safiri S,Carson-Chahhoud K,Noori M,et al.Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories,1990-2019:results from the Global Burden of Disease Study 2019[J].BMJ,2022,378:e069679.
23
Zhong N,Wang C,Yao W,et al.Prevalence of chronic obstructive pulmonary disease in China:a large,population-based survey[J].Am J Respir Crit Care Med,2007,176(8):753-60.
24
Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study):A national cross-sectional study [J].Lancet,391(10131):1706-1717.
25
Hu W,Fang L,Zhang H,et al.Global disease burden of COPD from 1990 to 2019 and prediction of future disease burden trend in China[J].Public health,2022,208:89-97.
26
Menezes AM,Perez-Padilla R,Jardim JR,et al.PLATINO Team.Chronic obstructive pulmonary disease in five Latin American cities(the PLATINO study):a prevalence study[J].Lancet,2005,366(9500):1875-1881.
27
任成山,王关嵩,钱桂生.慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD].中华肺部疾病杂志(电子版),2019,12(2):127-141.
[1] 张晋伟, 董永红, 王家璇. 基于GBD2021 数据库对中国与全球老年人疝疾病负担和健康不平等的分析比较[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 708-716.
[2] 王丹, 李文思, 成苏杭, 吉泽, 朱祥, 郝春艳. Treg/Th17 及DC 细胞水平在COPD不同疾病进展期的表达及其与预后的关系[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 685-689.
[3] 沈琪乐, 赵勤华, 宫素岗, 刘锦铭, 王岚, 邱宏玲. COPD 稳定期患者血清CC16 蛋白表达与肺功能、肺气肿表型的关系分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 690-695.
[4] 郭璟琪, 魏明言, 刘芳, 李冬凌, 关金平, 李立华. 乙酰半胱氨酸治疗慢性阻塞性肺疾病急性加重期的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 768-772.
[5] 王石林, 叶继章, 丘向艳, 陈桂青, 邹晓敏. 慢性阻塞性肺疾病真菌感染风险早期预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 773-776.
[6] 赵小欢, 尚志英, 段文超, 张晓燕, 孙东强. 无创通气治疗COPD 并发呼吸衰竭不同预后患者外周血MicroRNA及炎性因子水平分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 777-780.
[7] 曹健, 冯高华, 周卫军, 陈诚, 沈王丰, 吴英姿. 补脾益肺膏联合肺康复训练治疗慢性阻塞性肺疾病的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 781-784.
[8] 詹济玮, 蔡柳春, 温琼娜, 郭石生, 温春妹, 温鹤明. 布地格福联合噻托溴铵治疗AECOPD 的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 823-826.
[9] 刘璐璐, 何羽. 慢性阻塞性肺病患者睡眠障碍的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 836-839.
[10] 陈嘉艺, 陈佳, 张曦, 张琦. 伴有“反晕征”的IgG4 相关性肺疾病一例并文献复习[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 844-846.
[11] 马锦芳, 何正光, 郑劲平. 盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病黏痰症患者的疗效和安全性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 568-574.
[12] 陈惠英, 邱敏珊, 邵汉权. 脓毒症诱发肠黏膜屏障功能损伤的风险因素模型构建与应用效果[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 448-452.
[13] 秦相清, 朱陈, 张海银. 构建诺模图模型预测肝硬化食管胃底静脉曲张出血的风险[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 330-335.
[14] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[15] 闫维, 张二明, 张克, 安欣华, 向平超. 北京市石景山区40岁及以上居民早期慢性阻塞性肺疾病异质性及影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 533-540.
阅读次数
全文


摘要